インヒビターやアゴニスト、モジュレーターを幅広く供給

抗体-薬物複合体（ADC）関連化合物

抗体-薬物複合体（ADC）研究に有用な 細胞傷害性の小分子、リンカーを提供。

Auristatin、Maitansine、Calicheamicinなど 複数の細胞毒素をラインナップ

抗体-薬物複合体（ADC）は、癌化学療法において新規な治療 形式で、パラダイムシフトを起こす大きな可能性を有しています。

高純度を保証するためにNMRおよびHPLCにより分析。
<table>
<thead>
<tr>
<th><strong>HY-15142</strong></th>
<th><strong>HY-1316</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Doxorubicin hydrochloride</strong></td>
<td><strong>Mitomycin C</strong></td>
</tr>
<tr>
<td>Doxorubicin hydrochloride is a Topoisomerase II (Top2) catalytic inhibitor, also is a broad spectrum antibiotic used in the treatment of cancers, with IC50 of 374 nM for Hela cells.</td>
<td>Mitomycin C is a DNA-damaging agent and small-molecule inhibitor effectively sensitize cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).</td>
</tr>
<tr>
<td><strong>Target:</strong> ADC Cytotoxin</td>
<td><strong>Effect:</strong> Inhibitor</td>
</tr>
<tr>
<td><strong>(CAS No.: 25316-40-9)</strong></td>
<td><strong>(CAS No.: 50-07-7)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>HY-B0015</strong></th>
<th><strong>HY-15162</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Paclitaxel</strong></td>
<td><strong>Monomethyl auristatin E</strong></td>
</tr>
<tr>
<td>Paclitaxel is a potent anticancer agent known to promote microtubule (MT) assembly, inhibit MT depolymerization, and change MT dynamics required for mitosis and cell proliferation.</td>
<td>Monomethyl auristatin E (MMAE) is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin, and also shows inhibition of antibody-drug conjugates (ADCs) activity.</td>
</tr>
<tr>
<td><strong>Target:</strong> ADC Cytotoxin</td>
<td><strong>Effect:</strong> Inhibitor</td>
</tr>
<tr>
<td><strong>(CAS No.: 33069-62-4)</strong></td>
<td><strong>(CAS No.: 474645-27-7)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>HY-18261</strong></th>
<th><strong>HY-79256</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INNO-206</strong></td>
<td><strong>MMAF-OMe</strong></td>
</tr>
<tr>
<td>INNO-206 is a produg of the anticancer agent doxorubicin, which is released from albumin under acidic conditions.</td>
<td>MMAF-OMe inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4-) cell lines, respectively.</td>
</tr>
<tr>
<td><strong>Target:</strong> ADC Cytotoxin</td>
<td><strong>Effect:</strong> Inhibitor</td>
</tr>
<tr>
<td><strong>(CAS No.: 1361644-26-9)</strong></td>
<td><strong>(CAS No.: 863971-12-4)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>HY-14519</strong></th>
<th><strong>HY-32735</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methotrexate</strong></td>
<td><strong>Triptolide</strong></td>
</tr>
<tr>
<td>Methotrexate is a traditional folate antagonist, with median IC50 of 78 nM for a 120 h drug exposure in a panel of six pediatric leukemia and lymphoma cell lines using the sulforhodamine B assay.</td>
<td>Triptolide is an inhibitor of heat shock factor (HSF1), inhibits HSP90-CDC37 binding and induces acetylation of HSP90, and also inhibits MDM2 expression in a dose-dependent manner with IC50 values range from 47 to 73 nM.</td>
</tr>
<tr>
<td><strong>Target:</strong> ADC Cytotoxin</td>
<td><strong>Effect:</strong> Inhibitor</td>
</tr>
<tr>
<td><strong>(CAS No.: 59-05-2)</strong></td>
<td><strong>(CAS No.: 38748-32-2)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>HY-19610</strong></th>
<th><strong>HY-13062</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>alpha-Amanitin</strong></td>
<td><strong>Daunorubicin Hydrochloride</strong></td>
</tr>
<tr>
<td>alpha-Amanitin is a potent inhibitor of DNA-dependent RNA polymerase II.</td>
<td>Daunorubicin hydrochloride is a topoisomerase II inhibitor.</td>
</tr>
<tr>
<td><strong>Target:</strong> ADC Cytotoxin</td>
<td><strong>Effect:</strong> Inhibitor</td>
</tr>
<tr>
<td><strong>(CAS No.: 23109-05-9)</strong></td>
<td><strong>(CAS No.: 23541-50-6)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>HY-19809</strong></th>
<th><strong>HY-13061</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Calicheamicin</strong></td>
<td><strong>Daun02</strong></td>
</tr>
<tr>
<td>Calicheamicin is a potent DNA-binding cytotoxic antibiotic.</td>
<td>Daun02 is converted by β-galactosidase to Daunorubicin, which is a topoisomerase inhibitor.</td>
</tr>
<tr>
<td><strong>Target:</strong> ADC Cytotoxin</td>
<td><strong>Effect:</strong> Inhibitor</td>
</tr>
<tr>
<td><strong>(CAS No.: 108212-75-5)</strong></td>
<td><strong>(CAS No.: 290304-24-4)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>HY-18580</strong></th>
<th><strong>HY-16700</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Campathecin</strong></td>
<td><strong>PNU-159682</strong></td>
</tr>
<tr>
<td>Campathecin is a potent DNA enzyme topoisomerase I (topo I) inhibitor, with IC50 and IC70 of 50 nM and 0.225 µM in breast cancer cell line MDA-MB-231.</td>
<td>PNU-159682, a highly potent metabolite of the anthracycline nemorubicin with outstanding cytotoxicity, is a topoisomerase inhibitor and ADCs cytotoxin.</td>
</tr>
<tr>
<td><strong>Target:</strong> ADC Cytotoxin</td>
<td><strong>Effect:</strong> Inhibitor</td>
</tr>
<tr>
<td><strong>(CAS No.: 7689-03-4)</strong></td>
<td><strong>(CAS No.: 202350-68-3)</strong></td>
</tr>
</tbody>
</table>

(全ての製品は試験研究用です。試験研究以外の用途にはご利用いただけません。）
| **HY-15739** | Ansamitocin P-3  
Ansamitocin P-3 is a maytansine analog which displays potent cytotoxicity against the human solid tumor cell lines A-549 and HT-29. Antibody drug conjugate cytotoxin. |
|---|---|
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 66584-72-3) |  
**HY-15162A** | D8-MMAE  
D8-MMAE (D8-Monomethyl auristatin E; D8-Vedotin) is a deuterated form of MMAE. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 2070009-72-0) |  
**HY-15581** | MMAD  
Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 203849-91-6) |  
**HY-15579A** | MMF Hydrochloride  
MMF hydrochloride is an antibulin agent that inhibit cell division; inhibits H3397 cell growth with an IC50 of 105 nM. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 1415246-68-2) |  
**HY-15580** | Dolastatin 10  
Dolastatin 10 (DLS 10; NSC 376128) is a potent antimitotic peptide from a marine animal, strongly inhibits microtubule assembly; Dolastatin and Dolastatin's analogs are the cytotoxic components in Antibody–drug conjugates design (eg. cAC10–) |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 110417-88-4) |  
**HY-15584** | Taltobulin  
Taltobulin (HTI-286; SPA-110) is an analogue of Hemiasterlin; potent tubulin inhibitor; ADCs cytotoxin. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 228266-40-8) |  
**HY-15474** | Maytansinol  
Maytansinol inhibits microtubule assembly and induces microtubule disassembly in vitro. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 57103-68-1) |  
**HY-15142A** | Doxorubicin  
Doxorubicin is a Topoisomerase II (Top2) catalytic inhibitor, also is a broad spectrum antibiotic used in the treatment of cancers, with IC50 of 374 nM for Hela cells. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 23214-92-8) |  
**HY-13082A** | Daunorubicin  
Daunorubicin is a topoisomerase II inhibitor. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 20830-81-3) |  
**HY-12522** | PF-06380101  
PF-06380101 is a novel cytotoxic Dolastatin 10 analogue; with excellent potencies in tumor cell proliferation assays and differential ADME properties when compared to other synthetic auristatin analogues that are used in the preparation of ADCs. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 23214-92-8) |  
**HY-19839** | Ansamitocin P 3'  
Ansamitocin P 3' exhibits antitumour activity, is an antibody drug conjugate cytotoxin. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 66547-09-9) |  
**HY-15583** | Auristatin F  
Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMA analog and cytotoxin in Antibody–drug conjugates. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 163768-50-1) |  
**HY-20584** | 10-Deacetyl-7-xylosyl paclitaxel  
10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 90332-63-1) |  
**HY-15582** | Auristatin E  
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody–drug conjugates. |
| Target: ADC Cytotoxin  
Effect: Inhibitor  
(CAS No.: 160800-57-7) |
### Antibody-drug Conjugate (ADC) Related

#### HY-15579
- **MMAF**
  - MMAF is an antitubulin agent that inhibit cell division; inhibits H3397 cell growth with an IC50 of 105 nM.
  - **Effect:** Inhibitor
  - **Target:** ADC Cytotoxin
  - **CAS No.:** 745017-94-1

#### HY-16281A
- **DOXO-EMCH**
  - DOXO-EMCH is a 6-maleimidocaproyl hydrazone derivative of Doxorubicin, is an albumin binding prodrug.
  - **Effect:** Inhibitor
  - **Target:** ADC Cytotoxin
  - **CAS No.:** 151038-96-9

#### HY-15995
- **Tubulysin A**
  - Tubulysin A(TubA) is a myxobacterial product that can function as an antiangiogenic agent in many in vitro assays; anti-microtubule, anti-mitotic, an apoptosis inducer, anticancer, anti-angiogenic, and antiproliferative.
  - **Effect:** Inhibitor
  - **Target:** ADC Cytotoxin
  - **CAS No.:** 205304-86-5

#### HY-15584B
- **Taltobulin hydrochloride**
  - Taltobulin hydrochloride is an analogue of Hemisterlin; potent tubulin inhibitor; ADCs cytotoxin.
  - **Effect:** Inhibitor
  - **Target:** ADC Cytotoxin
  - **CAS No.:** 228266-41-9

#### HY-18261A
- **DOXO-EMCH**
  - DOXO-EMCH is a 6-maleimidocaproyl hydrazone derivative of Doxorubicin, is an albumin binding prodrug.
  - **Effect:** Inhibitor
  - **Target:** ADC Cytotoxin
  - **CAS No.:** 745017-94-1

#### HY-15584A
- **Taltobulin trifluoracetate**
  - Taltobulin trifluoracetate (HTI-286; SPA-110) is an analogue of Hemiasterlin; potent tubulin inhibitor; ADCs cytotoxin.
  - **Effect:** Inhibitor
  - **Target:** ADC Cytotoxin
  - **CAS No.:** 173441-26-4

#### HY-79105
- **MMAD hydrochloride**
  - Monomethyl auristatin D Hcl (MMAD Hcl), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.
  - **Effect:** Inhibitor
  - **Target:** ADC Cytotoxin
  - **CAS No.:** 159857-79-1

#### HY-20336
- **Mc-Val-Cit-PABC-PNP**
  - Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC peptide linker.
  - **Effect:** Inhibitor
  - **Target:** ADC Linker
  - **CAS No.:** 159857-81-5

#### HY-21210
- **6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)-**
  - 6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)- is an useful linker for antibody-drug-conjugations (ADCs), extracted from [Bioorg Chem. 2012 Apr-Jun;41-42:1-5.] compound 1i.
  - **Effect:** Inhibitor
  - **Target:** ADC Linker
  - **CAS No.:** 32602-11-2

#### HY-87881
- **6-Maleimidoheptanoic acid N-hydroxysuccinimide ester**
  - 6-Maleimidoheptanoic acid N-hydroxysuccinimide ester(ECMS) is a useful protective group in antibody drug conjugates.
  - **Effect:** Inhibitor
  - **Target:** ADC Linker
  - **CAS No.:** 55750-63-5

#### HY-19318
- **Fmoc-Val-Cit-PAB-PNP**
  - Fmoc-Val-Cit-PAB-PNP is a peptide prodrug linker, is a linker for antibody-drug-conjugation (ADC).
  - **Effect:** Inhibitor
  - **Target:** ADC Linker
  - **CAS No.:** 159857-79-1

#### HY-20560
- **(Ac)Phe-Lys(Alloc)-PABC-PNP**
  - (Ac)Phe-Lys(Alloc)-PABC-PNP is a useful chemical linker in antibody drug conjugates.
  - **Effect:** Inhibitor
  - **Target:** ADC Linker
  - **CAS No.:** 646502-53-6

#### HY-15575
- **VoMMAE**
  - VoMMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
  - **Effect:** Inhibitor
  - **Target:** Drug-Linker Conjugates for ADC
  - **CAS No.:** 646502-53-6
## Antibody-drug Conjugate (ADC) Related Compounds

<table>
<thead>
<tr>
<th>Compound</th>
<th>Target</th>
<th>Effect</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HY-19792</strong>&lt;br&gt;Mertansine</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 139504-50-0)</td>
<td>Mertansine is a tubulin inhibitor, inhibits the assembly of microtubules by binding to tubulin, with a linker structure can create an antibody-drug conjugate (ADC).</td>
</tr>
<tr>
<td><strong>HY-15741</strong>&lt;br&gt;Mc-MMAE</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 863971-24-8)</td>
<td>Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate; Mc-MMAE is a protective group (maleimidocaproyl) -conjugated MMAE.</td>
</tr>
<tr>
<td><strong>HY-100587</strong>&lt;br&gt;MAL-di-EG-Val-Cit-PAB-MMAE</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 1228105-51-8)</td>
<td>MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), MAL-di-EG-Val-Cit-PAB-MMAE is an antibody drug conjugate.</td>
</tr>
<tr>
<td><strong>HY-100374</strong>&lt;br&gt;SMCC-DM1</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 644981-35-1)</td>
<td>SMCC-DM1 is DM1 with a reactive linker SMCC to make antibody drug conjugate.</td>
</tr>
<tr>
<td><strong>HY-15740</strong>&lt;br&gt;Mc-MMAD</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 1401963-15-2)</td>
<td>Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate; Mc-MMAD is a protective group (maleimidocaproyl) -conjugated MMAD.</td>
</tr>
<tr>
<td><strong>HY-19813</strong>&lt;br&gt;mDPR-Val-Cit-PAB-MMAE</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 1491152-26-1)</td>
<td>mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate.</td>
</tr>
<tr>
<td><strong>HY-15742</strong>&lt;br&gt;Vc-MMAD</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 1401963-17-4)</td>
<td>Vc-MMAD consists the ADCs linker(Val-Cit) and potent tubulin inhibitor (MMAD), Vc-MMAD is an antibody drug conjugate.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Compound</th>
<th>Target</th>
<th>Effect</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HY-19812</strong>&lt;br&gt;Acetylene-linker-Val-Cit-PABC-MMAE</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 1411977-95-1)</td>
<td>Acetylene-linker-Val-Cit-PABC-MMAE consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE is an antibody drug conjugate.</td>
</tr>
<tr>
<td><strong>HY-15578</strong>&lt;br&gt;McMMAF</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 863971-19-1)</td>
<td>Mc-MMAF is a protective group-conjugated MMAF. MMAF is more potent drug than Monomethyl auristatin E (MMAE), but is charged and relatively membrane-impermeable, is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.</td>
</tr>
<tr>
<td><strong>HY-100586</strong>&lt;br&gt;SuO-Val-Cit-PAB-MMAE</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 644981-35-1)</td>
<td>SuO-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the peptide SuO-Val-Cit-PAB.</td>
</tr>
<tr>
<td><strong>HY-15750</strong>&lt;br&gt;Cys-mcMMAD</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 1401963-17-4)</td>
<td>Monomethyl auristatin D (MMAD), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.</td>
</tr>
<tr>
<td><strong>HY-19811</strong>&lt;br&gt;Fmoc-Val-Cit-PAB-MMAE</td>
<td>Drug-Linker Conjugates for ADC&lt;br&gt;Inhibitor</td>
<td>(CAS No. : 1350456-56-2)</td>
<td>Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), Fmoc-Val-Cit-PAB-MMAE is an antibody drug conjugate.</td>
</tr>
</tbody>
</table>